12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 01/18 13:06
Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 01/11 18:15
ATHX, AVCT and TPST among mi-day movers
Seeking Alpha · 01/11 17:44
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/11 17:30
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent With Clinical Benefit Observed In Patients With Cancer
Benzinga · 11/10/2022 14:05
BRIEF-Tempest Reports Q3 Financial Results, Provides Business Update
Reuters · 11/08/2022 13:56
Tempest Therapeutics Q3 EPS $(0.66) Up From $(1.21) YoY
Benzinga · 11/08/2022 13:14
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” SessionNicholas DeVito, M.D, Duke University School of Medicine, to present TPST-1495 preclinical data SOUTH SAN FRANCISCO, Calif., Oct....
GlobeNewswire · 10/06/2022 12:00
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
Benzinga · 09/15/2022 14:16
Ladenburg Thalmann Initiates Coverage On Tempest Therapeutics with Buy Rating, Announces Price Target of $8
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Buy rating and announces Price Target of $8.
Benzinga · 09/15/2022 12:40
--Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target
--Ladenburg Thalmann Starts Tempest Therapeutics at Buy With $8 Price Target
MT Newswires · 09/15/2022 09:03
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.
Benzinga · 08/22/2022 14:46
Tempest Therapeutics GAAP EPS of -$0.79
Tempest Therapeutics press release (<span class="ticker...
Seekingalpha · 08/15/2022 12:32
BRIEF-Tempest Therapeutics reports Q2 results
BRIEF-Tempest Therapeutics reports Q2 results
Reuters · 08/15/2022 12:18
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference
President Tom Dubensky, Ph.D., to Share Expertise on Next Generation Immuno-Oncolgy TargetsSOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class...
GlobeNewswire · 07/07/2022 12:00
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results And Updated Financial Guidance
  TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpected RECIST responses observed with TPST-1120 combined with
Benzinga · 06/09/2022 12:03
BRIEF-Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance · 06/09/2022 12:02
Tempest to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced t...
GlobeNewswire · 06/06/2022 20:05
41 Stocks Moving In Friday's Mid-Day Session
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Benzinga · 05/27/2022 18:13
AVDL, SIGA, PSHG and IOVA among mid-day movers
 Gainers: Avadel Pharmaceuticals (AVDL) +123%. SIGA Technologies (SIGA) +40%. Concert Pharmaceuticals (CNCE) +30%. Farfetch (FTCH) +25%. Allarity Therapeutics (ALLR) +25%. Merus N.V. (MRUS) +23%. Tenon Medical (TNON) +22%. Arcturus Therapeutics Holdings (A...
Seekingalpha · 05/27/2022 16:56
Webull provides a variety of real-time TPST stock news. You can receive the latest news about Tempest Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TPST
Tempest Therapeutics, Inc. (Tempest) is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.